Development of guidelines on nonoccupational HIV postexposure prophylaxis for the state of Rhode Island

Public Health Reports

Volumn 119, Issue 2, 2004, Pages 136-140

  Merchant, Roland C ^a,b   Mayer, Kenneth H ^a,c,d   Browning, Carol A ^e  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c Brown University AIDS Program   (United States)

^d MIRIAM HOSPITAL   (United States)

^e RHODE ISLAND DEPARTMENT OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; LAMIVUDINE; NELFINAVIR; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLOOD; BODY FLUID; EXPOSURE; HEALTH PRACTITIONER; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INTRAVENOUS DRUG ABUSE; MEDICAL EDUCATION; NEEDLESTICK INJURY; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SEXUAL CRIME; SEXUAL INTERCOURSE; UNITED STATES; VIRUS TRANSMISSION;

EID: 2442712700     PISSN: 00333549     EISSN: None     Source Type: Journal    
DOI: 10.1177/003335490411900205     Document Type: Review

References (12)

1. Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R, Abiteboul D, et al. Centers for Disease Control and Prevention Needlestick Surveillance Group. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med 1997;337:1485-90.
2. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331:1173-80.
3. Shaffer N, Chuachoowong R, Mock PA, Bhadrakom C, Siriwasin W, Young NL, et al. Bangkok Collaborative Perinatal HIV Transmission Study Group. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet 1999; 353(9155):773-80.
4. Blauvelt A. The role of skin dendritic cells in the initiation of human immunodeficiency virus infection. Am J Med 1997;102:16-20.
5. Tsai CC, Emau P, Sun JC, Beck TW, Tran CA, Follis KE, et al. Post-exposure chemoprophylaxis (PECP) against SIV infection of macaques as a model for protection from HIV infection. J Med Primatol 2000;29:248-58.
6. Rey D, Bendiane M-K, Moatti JP, Wellings K, Danziger R, MacDowall W. European Study Group on HIV Testing Policies and Practices in Europe. Post-exposure prophylaxis after occupational and non-occupational exposures to HIV: an overview of the policies implemented in 27 European countries. AIDS Care 2000;12:695-701.
7. Update: provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV. MMWR Morb Mortal Wkly Rep 1996;45:468-80.
8. Management of possible sexual, injecting-drug-use, or other nonoccupational exposure to HIV, including considerations related to antiretroviral therapy: Public Health Service statement. MMWR Recomm Rep 1998; 47(RR-17):1-14.
9. AIDS Institute, New York State Department of Health. HIV prophylaxis following sexual assault: guidelines for adults and adolescents. New York: New York State Department of Health, AIDS Institute; 1998.
10. Myles JE, Bamberger J. Offering HIV prophylaxis following sexual assault: recommendations for the state of California. San Francisco: California HIV Postexposure Prophylaxis after Sexual Assault Task Force; 2001.
11. Commonwealth of Massachusetts, Department of Health. Clinical advisory: HIV prophylaxis for nonoccupational exposures. Boston: Massachusetts Department of Public Health; 2000.
12. Merchant RC, Mayer KH, Browning CA. Nonoccupational HIV Postexposure Prophylaxis Task Force. Nonoccupational human immunodeficiency virus postexposure prophylaxis guidelines for Rhode Island healthcare practitioners. Providence: Brown University AIDS Program and Rhode Island Department of Health; 2002.